BMS's kingly Opdivo NSCLC data

Bristol-Myers Squibb Co. (NYSE:BMY) said it ended the Phase III CheckMate -017 trial of Opdivo nivolumab to treat advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) after an independent data monitoring committee concluded the drug met the trial's primary endpoint of superior overall survival compared to a control arm.

Patients who received 3 mg/kg of IV Opdivo every two weeks had superior overall survival compared to those who received 75 mg/m^2 of IV docetaxel every three weeks. BMS spokesperson Carrie Fernandez declined to disclose when it would present full data from CheckMate -017. ...